Zeo ScientifiX Business Summary

Zeo ScientifiX, Inc. (ZEOX) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of regenerative biological therapeutics for degenerative diseases. The company generates revenue through two primary segments: the sale of its flagship allogeneic product, Zofin™ (an acellular, perinatal-derived biologic), and its autologous Patient Pure X™ (PPX™) service platform, which processes a patient’s own peripheral blood to isolate bioactive nanoparticles. For the fiscal year ending October 31, 2025, ZEOX reported $5.2 million in revenue, a 12.5% year-over-year increase driven largely by the expansion of the PPX platform. The company’s current market strategy leverages Florida’s SB 1768 law to provide non-FDA-approved regenerative treatments directly to clinicians, positioning itself as a specialized provider of nanoparticle-based cell-free therapies. In the competitive landscape, ZEOX contends with players like Flexion Therapeutics, MediciNova, and Aegle Therapeutics, differentiating itself through its proprietary isolation processes and focus on high-potency, standardized biologics. The leadership team is led by Ian T. Bothwell, who was appointed full-time Chief Executive Officer and Chief Financial Officer in December 2025, bringing nearly a decade of executive experience within the firm’s predecessor, Organicell. The clinical and scientific strategy is directed by Chief Medical Officer Dr. George Shapiro, a pioneer in age-management medicine, and Chief Science Officer Dr. John D. Kisiday, who joined in January 2026 with 30 years of expertise in tissue engineering and orthobiologics. Dr. Peter A. M. Everts serves as the Chief Scientific and Technology Officer, overseeing the technical advancement of the company’s exosome-based ZEO-platform. Governance is managed by a board chaired by Chuck Bretz, with significant strategic influence held by major investor Wendy Grey of Greyt Ventures, LLC, who controls approximately 43% of the company’s aggregate voting power as of February 2026.